ProAir Digihaler
Total Payments
$2.0M
Transactions
2,759
Doctors
1,682
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $275,091 | 14 | 3 |
| 2023 | $9,506 | 45 | 31 |
| 2022 | $593,390 | 311 | 182 |
| 2021 | $1.0M | 1,207 | 855 |
| 2020 | $77,405 | 1,182 | 761 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.6M | 85 | 79.9% |
| Consulting Fee | $171,277 | 42 | 8.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $169,670 | 91 | 8.6% |
| Food and Beverage | $51,131 | 2,521 | 2.6% |
| Travel and Lodging | $4,693 | 20 | 0.2% |
Payments by Type
Research
$1.6M
85 transactions
General
$396,771
2,674 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Utilizing Advances in Digital Inhaler Technology to Understand Heterogeneous Treatment Responses to Biologics in Severe Asthma | Teva Pharmaceuticals USA, Inc. | $1.2M | 0 |
| ProAir Digihaler in COPD Disease Management: A real world study to assess ProAir Digihaler inhalation parameters thresholds and their use to identify deterioration in clinical practice | Teva Pharmaceuticals USA, Inc. | $230,462 | 0 |
| Albuterol Integrated Adherence Monitoring in Children with Asthma | Teva Pharmaceuticals USA, Inc. | $80,543 | 0 |
| Expert consensus on SABA use for asthma clinical decision-making: a Delphi approach | Teva Pharmaceuticals USA, Inc. | $10,016 | 7 |
| US expert consensus on short-acting beta-agonist reliever medication use for asthma clinical decision-making: a mixed-method Delphi adjudication approach | Teva Pharmaceuticals USA, Inc. | $6,532 | 5 |
| US Expert Consensus On Short-acting Beta Agonist (SABA) Reliever Medication Use For Asthma Clinical Decision-making: A Mixed-method Delphi Adjudication Approach | Teva Pharmaceuticals USA, Inc. | $4,390 | 7 |
| Rescue use COPD review article | Teva Pharmaceuticals USA, Inc. | $3,207 | 4 |
| Reliever use COPD review article | Teva Pharmaceuticals USA, Inc. | $935.43 | 3 |
Top Doctors Receiving Payments for ProAir Digihaler — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Pulmonary Disease | Arecibo, PR | $1,680 | 1 |
| , M.D | Allergy & Immunology | Canton, MI | $1,680 | 1 |
| , M.D | Allergy & Immunology | Pensacola, FL | $1,680 | 1 |
| , M.D | Internal Medicine | Albany, NY | $1,680 | 1 |
| , D.O | Allergy | Lakewood, WA | $1,680 | 1 |
| , M.D | Allergy & Immunology | Ocean, NJ | $1,680 | 1 |
| , M.D | Pediatrics | Marrero, LA | $1,680 | 1 |
| , MD | Critical Care Medicine | New York, NY | $1,114 | 2 |
| , MD | Pulmonary Disease | Knoxville, TN | $1,000 | 1 |
| , MD | Allergy & Immunology | Sheboygan, WI | $1,000 | 1 |
| , MD | Internal Medicine | Ann Arbor, MI | $801.79 | 1 |
| , MD | Allergy & Immunology | Brooklyn, NY | $575.07 | 1 |
| , MD | Internal Medicine | Ann Arbor, MI | $381.99 | 4 |
| , MD | Allergy & Immunology | Huntingtn Bch, CA | $235.00 | 3 |
| , M.D | Allergy & Immunology | Atlanta, GA | $226.22 | 14 |
| , M.D | Allergy | Gainesville, GA | $222.26 | 14 |
| , NP-C | Adult Health | Wrightsville, GA | $221.34 | 15 |
| , M.D | Allergy & Immunology | Powderly, KY | $204.34 | 4 |
| , M.D | Allergy & Immunology | Houston, TX | $180.30 | 4 |
| , MD | Critical Care Medicine | Decatur, GA | $177.71 | 12 |
| , MD | Pulmonary Disease | Johns Creek, GA | $163.59 | 10 |
| , DO | Internal Medicine | Pearland, TX | $160.81 | 3 |
| , M.D | Emergency Medicine | Midlothian, VA | $160.23 | 1 |
| , MD | Allergy & Immunology | Gainesville, GA | $152.35 | 9 |
| , DDS | Endodontics | La Jolla, CA | $152.00 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.0M
- Total Doctors 1,682
- Transactions 2,759
About ProAir Digihaler
ProAir Digihaler is a drug associated with $2.0M in payments to 1,682 healthcare providers, recorded across 2,759 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2020 to 2024. In 2024, $275,091 was paid across 14 transactions to 3 doctors.
The most common payment nature for ProAir Digihaler is "Unspecified" ($1.6M, 79.9% of total).
ProAir Digihaler is associated with 8 research studies, including "Utilizing Advances in Digital Inhaler Technology to Understand Heterogeneous Treatment Responses to Biologics in Severe Asthma" ($1.2M).